Bausch & Lomb optimistic on FDA approval for laser
This article was originally published in Clinica
The share price of eye healthcare company Bausch & Lomb rose by nearly 8% last week on the announcement that the company was "highly confident" that the US FDA would waive a panel review of its pre-market approval application by the ophthalmic devices panel for its laser for LASIK refractive surgery procedures.
You may also be interested in...
Topline results with AZD1222 have shown a lower efficacy rate than the Pfizer and Moderna vaccines, but a subgroup receiving a half-dose in their first injection showed a 90% efficacy result.
Krka’s bottom line continues to be stronger than usual, driven by a hike in sales and leaner cost base. Looking to 2021, however, management brought investors back down to earth.
The COVID-19 pandemic has triggered extraordinary levels of collaboration. But competition remains, and many newly created coalitions have yet to be stress tested.